Therapeutic approaches to Epstein–Barr virus cancers
Epstein–Barr virus (EBV) establishes a lifelong latent infection that can be a causal agent for a diverse spectrum of cancers and autoimmune disease. A complex and dynamic viral lifecycle evades eradication by the host immune system and confounds antiviral therapeutic strategies. To date, there are...
Gespeichert in:
| Veröffentlicht in: | Current opinion in virology 2022-10, Vol.56, p.101260-101260, Article 101260 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101260 |
|---|---|
| container_issue | |
| container_start_page | 101260 |
| container_title | Current opinion in virology |
| container_volume | 56 |
| creator | Soldan, Samantha S Messick, Troy E Lieberman, Paul M |
| description | Epstein–Barr virus (EBV) establishes a lifelong latent infection that can be a causal agent for a diverse spectrum of cancers and autoimmune disease. A complex and dynamic viral lifecycle evades eradication by the host immune system and confounds antiviral therapeutic strategies. To date, there are no clinically approved vaccines or therapies that selectively target EBV as the underlying cause of EBV-associated disease. Here, we review the challenges and recent advances in the development of EBV-specific therapeutics for treatment of EBV-associated cancers. |
| doi_str_mv | 10.1016/j.coviro.2022.101260 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11058316</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1879625722000712</els_id><sourcerecordid>2720425687</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-3362979c0bbe4c844284b7eedbbe9831073854ddbf73f6a494126a409652d9733</originalsourceid><addsrcrecordid>eNp9kM1OAyEUhYnR2Kb2DYyZpZtWYBgYNhpt6k_SxE1dE4a5tTTtMMJME3e-g2_ok0gztdGNbC5czj0HPoTOCR4TTPjVamzc1no3ppjSXYtyfIT6JBdyxCnPjg_7TPTQMIQVjivjRGbkFPVSTgRjkvcRny_B6xraxppE17V32iwhJI1LpnVowFZfH5932vskxrUhMboy4MMZOlnodYDhvg7Qy_10PnkczZ4fnia3s5FhnDWjNOVUCmlwUQAzOWM0Z4UAKONZ5inBIs0zVpbFQqQLrplk8SOaYckzWkqRpgN00_nWbbGB0kDVeL1Wtbcb7d-V01b9vansUr26rSIEZzGAR4fLvYN3by2ERm1sMLBe6wpcGxQVFDOa8VxEKeukxrsQPCwOOQSrHXa1Uh12tcOuOuxx7OL3Gw9DP5Cj4LoTQCS1teBVMBYix9J6MI0qnf0_4RvATJYZ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2720425687</pqid></control><display><type>article</type><title>Therapeutic approaches to Epstein–Barr virus cancers</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Soldan, Samantha S ; Messick, Troy E ; Lieberman, Paul M</creator><creatorcontrib>Soldan, Samantha S ; Messick, Troy E ; Lieberman, Paul M</creatorcontrib><description>Epstein–Barr virus (EBV) establishes a lifelong latent infection that can be a causal agent for a diverse spectrum of cancers and autoimmune disease. A complex and dynamic viral lifecycle evades eradication by the host immune system and confounds antiviral therapeutic strategies. To date, there are no clinically approved vaccines or therapies that selectively target EBV as the underlying cause of EBV-associated disease. Here, we review the challenges and recent advances in the development of EBV-specific therapeutics for treatment of EBV-associated cancers.</description><identifier>ISSN: 1879-6257</identifier><identifier>ISSN: 1879-6265</identifier><identifier>EISSN: 1879-6265</identifier><identifier>DOI: 10.1016/j.coviro.2022.101260</identifier><identifier>PMID: 36174496</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><ispartof>Current opinion in virology, 2022-10, Vol.56, p.101260-101260, Article 101260</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-3362979c0bbe4c844284b7eedbbe9831073854ddbf73f6a494126a409652d9733</citedby><cites>FETCH-LOGICAL-c464t-3362979c0bbe4c844284b7eedbbe9831073854ddbf73f6a494126a409652d9733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.coviro.2022.101260$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36174496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soldan, Samantha S</creatorcontrib><creatorcontrib>Messick, Troy E</creatorcontrib><creatorcontrib>Lieberman, Paul M</creatorcontrib><title>Therapeutic approaches to Epstein–Barr virus cancers</title><title>Current opinion in virology</title><addtitle>Curr Opin Virol</addtitle><description>Epstein–Barr virus (EBV) establishes a lifelong latent infection that can be a causal agent for a diverse spectrum of cancers and autoimmune disease. A complex and dynamic viral lifecycle evades eradication by the host immune system and confounds antiviral therapeutic strategies. To date, there are no clinically approved vaccines or therapies that selectively target EBV as the underlying cause of EBV-associated disease. Here, we review the challenges and recent advances in the development of EBV-specific therapeutics for treatment of EBV-associated cancers.</description><issn>1879-6257</issn><issn>1879-6265</issn><issn>1879-6265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OAyEUhYnR2Kb2DYyZpZtWYBgYNhpt6k_SxE1dE4a5tTTtMMJME3e-g2_ok0gztdGNbC5czj0HPoTOCR4TTPjVamzc1no3ppjSXYtyfIT6JBdyxCnPjg_7TPTQMIQVjivjRGbkFPVSTgRjkvcRny_B6xraxppE17V32iwhJI1LpnVowFZfH5932vskxrUhMboy4MMZOlnodYDhvg7Qy_10PnkczZ4fnia3s5FhnDWjNOVUCmlwUQAzOWM0Z4UAKONZ5inBIs0zVpbFQqQLrplk8SOaYckzWkqRpgN00_nWbbGB0kDVeL1Wtbcb7d-V01b9vansUr26rSIEZzGAR4fLvYN3by2ERm1sMLBe6wpcGxQVFDOa8VxEKeukxrsQPCwOOQSrHXa1Uh12tcOuOuxx7OL3Gw9DP5Cj4LoTQCS1teBVMBYix9J6MI0qnf0_4RvATJYZ</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Soldan, Samantha S</creator><creator>Messick, Troy E</creator><creator>Lieberman, Paul M</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221001</creationdate><title>Therapeutic approaches to Epstein–Barr virus cancers</title><author>Soldan, Samantha S ; Messick, Troy E ; Lieberman, Paul M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-3362979c0bbe4c844284b7eedbbe9831073854ddbf73f6a494126a409652d9733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soldan, Samantha S</creatorcontrib><creatorcontrib>Messick, Troy E</creatorcontrib><creatorcontrib>Lieberman, Paul M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current opinion in virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soldan, Samantha S</au><au>Messick, Troy E</au><au>Lieberman, Paul M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic approaches to Epstein–Barr virus cancers</atitle><jtitle>Current opinion in virology</jtitle><addtitle>Curr Opin Virol</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>56</volume><spage>101260</spage><epage>101260</epage><pages>101260-101260</pages><artnum>101260</artnum><issn>1879-6257</issn><issn>1879-6265</issn><eissn>1879-6265</eissn><abstract>Epstein–Barr virus (EBV) establishes a lifelong latent infection that can be a causal agent for a diverse spectrum of cancers and autoimmune disease. A complex and dynamic viral lifecycle evades eradication by the host immune system and confounds antiviral therapeutic strategies. To date, there are no clinically approved vaccines or therapies that selectively target EBV as the underlying cause of EBV-associated disease. Here, we review the challenges and recent advances in the development of EBV-specific therapeutics for treatment of EBV-associated cancers.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>36174496</pmid><doi>10.1016/j.coviro.2022.101260</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1879-6257 |
| ispartof | Current opinion in virology, 2022-10, Vol.56, p.101260-101260, Article 101260 |
| issn | 1879-6257 1879-6265 1879-6265 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11058316 |
| source | Elsevier ScienceDirect Journals Complete |
| title | Therapeutic approaches to Epstein–Barr virus cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T10%3A41%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20approaches%20to%20Epstein%E2%80%93Barr%20virus%20cancers&rft.jtitle=Current%20opinion%20in%20virology&rft.au=Soldan,%20Samantha%20S&rft.date=2022-10-01&rft.volume=56&rft.spage=101260&rft.epage=101260&rft.pages=101260-101260&rft.artnum=101260&rft.issn=1879-6257&rft.eissn=1879-6265&rft_id=info:doi/10.1016/j.coviro.2022.101260&rft_dat=%3Cproquest_pubme%3E2720425687%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2720425687&rft_id=info:pmid/36174496&rft_els_id=S1879625722000712&rfr_iscdi=true |